Know Cancer

forgot password

Phase II Study of Letrozole in Patients With Recurrent Advanced Borderline Tumors or Low Grade Epithelial Cancers of the Ovary, Fallopian Tube and Primary Peritoneum

Phase 2
18 Years
Not Enrolling
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Thank you

Trial Information

Phase II Study of Letrozole in Patients With Recurrent Advanced Borderline Tumors or Low Grade Epithelial Cancers of the Ovary, Fallopian Tube and Primary Peritoneum

Letrozole is an anticancer hormone that is FDA approved for use in patients with advanced
breast cancer.

Before you can be enrolled in this study, you must go through some screening tests to make
sure you are eligible. The screening tests include a complete medical history and physical
exam, including measurement of your pulse rate, breathing rate, temperature, height, weight,
and blood pressure. The physical examination will also include measurement of any visible
cancer lesions. You will be asked what medications you are taking, including over the
counter medications, herbal medications, and vitamins. You will have chest x-rays and/or CT
or MRI scans to measure the size of your tumors. You will have routine blood tests (about 2
and a 1/2 tablespoons) performed.

If you qualify for the study, you will take Letrozole once a day by mouth. Letrozole will
be dispensed in the form of a tablet. Four to eight weeks worth of Letrozole will be
prescribed to you by your treatment doctor at each visit. You will continue to receive
Letrozole as long as you are responding to treatment.

You will be required to come back for check-up at least once every 2 months while on study
for the first two years. You should contact the study doctor if you feel unwell or feel the
need to see the doctor before your appointment earlier than your designated appointment.

At each follow-up visit, you will have a complete physical exam. The chest x-rays and/or CT
or MRI scans will be repeated every 2 months, and at the time you complete the trial, or at
any other time if necessary. Blood tests (about 1 tablespoon) will be performed every 2
months. Information about the medications you are taking, or medical problems you have had
since your last visit will be collected. At each follow-up visit, you will also be asked to
complete a one page, paper and pencil check off sheet. You will be asked to identify
symptoms you may be having and to note the amount of distress each symptom is causing you.

You will be taken off study if the disease gets worse or intolerable side effects occur and
your doctor will discuss possible treatment options with you.

However, as long as you continue to benefit from Letrozole treatment, you will continue on
this treatment. If you are on letrozole treatment beyond two years, you will be followed up
at three months interval. At these follow up visits, you will be asked questions about your
medical history and have a physical exam. You will also have blood (about tablespoon) and
urine tests, and/or radiological evaluation of the tumor. As long as you continue to
benefit from letrozole treatment, you will be followed up.

Your status will be followed for as long as possible even after you are taken off the study
drug. You will be contacted by phone or asked to come to the clinic for a routine visit.
You will be contacted every 6 weeks for 1 year after the study and every 12 weeks for the
rest of your life.

This is an investigational study. Letrozole is not approved by the FDA for the treatment of
recurrent low grade or borderline ovarian, fallopian tube or primary peritoneal cancer. A
total of up to 80 patients will take part in this study. All will be enrolled at M. D.

Inclusion Criteria:

1. History of histologically confirmed diagnosis of borderline tumors or low-grade
epithelial cancer from the ovary, fallopian tube or primary peritoneum. Eligible
histologies include borderline serous papillary, borderline mucinous papillary,
borderline endometrioid, low-grade serous papillary, low-grade mucinous papillary,
low-grade endometrioid and mixture of the above. Patients whose tumors are
histologically borderline but have low grade invasive implants are also included.
Patients whose tumors are histologically borderline but which include high grade
components are excluded.

2. Recurrent or advanced borderline or low-grade epithelial ovarian, fallopian tube or
primary peritoneal tumors not amenable to surgery, or patients who have measurable
residual disease at the end of secondary cytoreduction.

3. The ovarian tumors have to be either estrogen receptor or progesterone receptor

4. Measurable disease by radiological imaging studies. Raised CA125 tumor marker alone
and lesions located in previously irradiated areas are not considered measurable.

5. Age greater than 18 years of age.

6. Expected survival of more than 12 weeks.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

8. Willingness to comply with study procedures and follow up examinations.

9. Have written informed consent. (Signature on consent form indicating that the patient
is aware of the nature of her disease and willingly gives written consent after being
informed of the procedure to be followed, the experimental nature of the therapy,
alternative treatment options and potential benefits and risks associated with the

10. Known history of Central nervous system metastases allowed if patients have had
treatment, are neurologically stable, and do not require oral or intravenous steroids
or anti-convulsants, provided brain scan (Computer Assisted Tomography or Magnetic
Resonance Imaging Scans) shows absence of active disease.

11. Have adequate bone marrow reserve as indicated by absolute neutrophil count (ANC)>
1,500/ mm3; platelet count > 100,000/mm3; hemoglobin > 9.0g/dL.

12. Have adequate liver function tests as indicated by bilirubin < 1.5 X normal, alanine
amino-transferase (ALT)< 3 X normal; and aspartate amino-transferase (AST) < 3 X

13. Have adequate renal function tests as indicated by serum creatinine of < 1.5mg/dl.

Exclusion Criteria:

1. Failure to recover from any prior surgery or major surgery within 4 weeks of study

2. Patients with sarcomatous, germ cell or stromal elements in their cancers are not

3. Patients with intermediate and high-grade primary ovarian, fallopian tube, and
primary peritoneal epithelial carcinoma. Patients whose tumors are histologically
borderline but which includes high grade components are excluded.

4. Pregnant or lactating women

5. Leptomeningeal or carcinomatous meningitis

6. Unstable medical conditions such as uncontrolled cardiac arrythmia or history of
myocardial infarction within 6 months

7. Any severe, concurrent disease, infection or co-morbidity that, in the judgment of
the investigator, would make the patient inappropriate for study entry.

8. Any signs of intestinal obstruction interfering with nutrition

9. Treatment with chemotherapy, radiotherapy, radiopharmaceuticals or immunotherapy
within 4 weeks of first study dosing with letrozole (within 6 weeks for nitrosureas
or mitomycin C) or failure to recover from the toxic effects of any of these
therapies prior to study entry.

10. Patients with more than 4 prior chemotherapy regimes with all platinum regimes
counted as one.

11. Patients who has had prior anti-cancer hormonal therapy for ovarian cancer with
aromatase inhibitors. Patients treated with gonadotrophin agonist, gonadotropin
antagonist and Selective estrogen receptor modulators (SERMS) are allowed. Patients
on hormone replacement therapy or who have had fertility treatment with estrogens and
gonadotropins are also allowed.

12. Patients on estrogen and progesterone replacement therapy must have a wash out period
of 4 weeks.

13. A history of prior malignancy except for adequately treated carcinoma in situ of the
cervix, basal cell or squamous cell skin cancer, or other cancer for which the
patient has not been disease- free for at least five years

14. Patients receiving concurrent chemotherapy, radiotherapy or immunotherapy.

15. Participation in any investigational drug study within 30 days of the first day of

16. Psychiatric disorders that would preclude obtaining informed consent and
participation in an ongoing research study

17. Patients with a known history of human immunodeficiency virus (HIV) infection

18. Patients with inadequately treated serious thromboembolic disease such as pulmonary
embolism and deep vein thrombosis, or with known clotting disorders.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate Following Treatment With Letrozole

Outcome Description:

Using RECIST criteria, Objective Response evaluated every 2 months.

Outcome Time Frame:

2 month intervals for first 2 years

Safety Issue:


Principal Investigator

John J. Kavanagh, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

September 2003

Completion Date:

May 2010

Related Keywords:

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer
  • Letrozole
  • Femara
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Fallopian Tube Neoplasms



U.T.M.D. Anderson Cancer CenterHouston, Texas  77030